טוען...
HOUT-09. USING THE ASCO AND ESMO FRAMEWORKS TO ASSESS THE CLINICAL VALUE OF TUMOR TREATING FIELDS FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
BACKGROUND: The effectivity and safety of TTFields in newly diagnosed GBM was recently demonstrated by the final analysis of the large, randomized controlled EF-14 Trial. To capture the clinical value of new cancer treatments, the American Society of Clinical Oncology (ASCO) and the European Society...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217041/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.477 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|